Migraine Drugs Market, By Treatment (Abortive or Acute and Prophylactic or Preventive), By Route of Administration (Oral, Injectable, and Others (Nasal Spray and Transdermal Patch)), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

More people experiencing migraine attacks

The market for migraine medications is being driven mainly by an increase in migraine attacks worldwide. For example, based on information released For example, in June 2018, the National Centre of Biotechnology Information published data indicating that the prevalence of migraines is estimated to be between 2.6% and 21.7% worldwide, with an average of ~12%. The target market is also being driven by the growing need for anti-migraine medications to either stop attacks or lessen their effects while they are occurring. For example, the National Centre of Biotechnology Information reports that erenumab was the first CGRP-receptor monoclonal antibody authorized by the US FDA in 2018 and was designed for the prevention of adult migraines.

People's unhealthy lifestyles

Furthermore, the market for migraine medications is anticipated to be driven throughout the forecast period by factors such as people's poor lifestyles, stress and worry, missing meals, bright light, and loud noises. The market for migraine medications is also being driven by the introduction of calcitonin gene-related peptide (CGRP)-based medicines, a rise in unmet demands, and the growing acceptance of innovative medication classes. In the near future, the target market is anticipated to grow due to an increasing emphasis on drug development.